New method for identifying proteins should have “a major impact on the development of new biologics,” U of T researcher says
Biologics are a type of drug that results from the high-tech manipulation of our own proteins, as opposed to more traditional drugs built from synthetic chemicals. Because of their success so far, scientists are racing to create new biologics – and now, a U of T researcher has developed a way to make that process more powerful.
Philip M. Kim, an associate professor in U of T’s Donnelly Centre for Cellular and Biomolecular Research, combined high-tech computer simulation and high-throughput laboratory experiments to create what he hopes will be the most effective way to discover the proteins that are key to new biologics. His research was published online in the journal Science Advances on July 20, 2016.
“A large fraction of new therapeutics these days involve engineered proteins that latch onto a drug target, for instance on a cancer cell,” says Kim, also of the departments of molecular genetics and computer science. “Finding a protein that effectively binds to a target can feel like looking for a needle in a haystack.
“Our method should open up new opportunities to find those key proteins – and make a major impact on the development of new biologics.”
Under the traditional approach to developing a biologic, researchers identify a protein of interest and then test billions of variants, either randomly generated or from a natural source, hoping to find an effective binder. But these methods allow very little control over where and how the protein performs this crucial function on its target – a major factor in its effectiveness.
Kim and his team took a different approach. They used a computer to simulate the binding process, and then designed proteins that would work on the target. This type of theoretical approach has been in development for several decades, but is still not effective enough. So Kim combined the best of both methods. Instead of randomly creating massive libraries of variants, as with the traditional approach, he used computer modelling to generate a smaller, but intelligently designed repertoire of variants. Designing each variant allows for the tight control of all its properties, in contrast to conventional approaches.
“We showed that this method gives you binders that are somewhat stronger than what you get with the conventional approach,” says Kim. “The much smaller library also solves many technical problems, and we can screen for new, previously unscreenable, targets. It’s a very exciting time for cancer research, and for biologics.”
For Kim, the next step is to produce proteins that are important to certain types of cancer, but have not been screened before due to the difficulty producing them.
Learn more: A more powerful way to develop therapeutics?
The Latest on: Biologics
via Google News
The Latest on: Biologics
- When It Comes to Biologics, Researchers Find Patient Education is Neededon August 16, 2019 at 6:10 am
New research shows that many people with lupus may lack awareness or understanding of biologic therapies, or “biologics” – treatments that use substances made from living organisms like proteins and ...
- Heat Biologics EPS in-line, misses on revenueon August 14, 2019 at 4:24 am
Heat Biologics (NASDAQ:HTBX): Q2 GAAP EPS of -$0.14 in-line. Grant and licensing revenue of $0.34M (-70.2% Y/Y) misses by $0.53M.
- Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Updateon August 14, 2019 at 4:00 am
August 14, 2019 (ACCESSWIRE via COMTEX) -- Completed enrollment of Phase 2non-small cell lung cancer trial; on track to report top line data later this year Received FDA clearance of IND application ...
- Global Biologics & Biosimilars Market By Current Industry Status, Growth Opportunities, Top Key Players, Target Audience And Forecast To 2025on August 13, 2019 at 4:15 am
Aug 13, 2019 (Garth Media via COMTEX) -- This report studies the global Biologics amp; Biosimilars market status and forecast, categorizes the global Biologics amp; Biosimilars market size (value amp; ...
- Synthetic Biologics, Inc (SYN) CEO Steven Shallcross on Q2 2019 Results - Earnings Call Transcripton August 8, 2019 at 10:24 pm
Synthetic Biologics, Inc (NYSEMKT:SYN) Q2 2019 Earnings Conference Call August 8, 2019 4:30 PM ET Company Participants Vincent Perrone - Director, Corporate Communication Steven Shallcross - Chief ...
- Synthetic Biologics Reports Second Quarter 2019 Operational Highlights and Financial Resultson August 8, 2019 at 1:15 pm
ROCKVILLE, Md., Aug. 8, 2019 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and ...
- ADMA Biologics Reports Second Quarter and First Half 2019 Financial Resultson August 8, 2019 at 5:08 am
RAMSEY, N.J. and BOCA RATON, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty ...
- Breakeven On The Horizon For ADMA Biologics, Inc. (NASDAQ:ADMA)on August 8, 2019 at 5:04 am
ADMA Biologics, Inc.'s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the ...
- Adma Biologics: 2Q Earnings Snapshoton August 8, 2019 at 4:17 am
RAMSEY, N.J. - (AP) _ Adma Biologics Inc. (ADMA) on Thursday reported a loss of $13.2 million in its second quarter. The Ramsey, New Jersey-based company said it had a loss of 25 cents per share. The ...
- Synthetic Biologics: 2Q Earnings Snapshoton August 8, 2019 at 4:00 am
ROCKVILLE, Md. (AP) _ Synthetic Biologics Inc. (SYN) on Thursday reported a loss of $3.5 million in its second quarter. The Rockville, Maryland-based company said it had a loss of 23 cents per share.
via Bing News